JP2016028035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016028035A5 JP2016028035A5 JP2015159434A JP2015159434A JP2016028035A5 JP 2016028035 A5 JP2016028035 A5 JP 2016028035A5 JP 2015159434 A JP2015159434 A JP 2015159434A JP 2015159434 A JP2015159434 A JP 2015159434A JP 2016028035 A5 JP2016028035 A5 JP 2016028035A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- cells
- deletion
- virus
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 244000309459 oncolytic virus Species 0.000 description 4
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 206010001258 Adenoviral infections Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682209P | 2009-03-02 | 2009-03-02 | |
| US61/156,822 | 2009-03-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553041A Division JP6072414B2 (ja) | 2009-03-02 | 2010-03-02 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018035231A Division JP6817979B2 (ja) | 2009-03-02 | 2018-02-28 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016028035A JP2016028035A (ja) | 2016-02-25 |
| JP2016028035A5 true JP2016028035A5 (enExample) | 2017-02-16 |
| JP6375273B2 JP6375273B2 (ja) | 2018-08-15 |
Family
ID=42710189
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553041A Active JP6072414B2 (ja) | 2009-03-02 | 2010-03-02 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2015159434A Active JP6375273B2 (ja) | 2009-03-02 | 2015-08-12 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2018035231A Active JP6817979B2 (ja) | 2009-03-02 | 2018-02-28 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2020019294A Pending JP2020078326A (ja) | 2009-03-02 | 2020-02-07 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2021158698A Active JP7326396B2 (ja) | 2009-03-02 | 2021-09-29 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553041A Active JP6072414B2 (ja) | 2009-03-02 | 2010-03-02 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018035231A Active JP6817979B2 (ja) | 2009-03-02 | 2018-02-28 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2020019294A Pending JP2020078326A (ja) | 2009-03-02 | 2020-02-07 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
| JP2021158698A Active JP7326396B2 (ja) | 2009-03-02 | 2021-09-29 | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9073980B2 (enExample) |
| EP (4) | EP4123030A1 (enExample) |
| JP (5) | JP6072414B2 (enExample) |
| KR (4) | KR102020018B1 (enExample) |
| CY (1) | CY1122385T1 (enExample) |
| DK (2) | DK2403951T3 (enExample) |
| ES (2) | ES2750305T3 (enExample) |
| HR (2) | HRP20151396T1 (enExample) |
| HU (2) | HUE026386T2 (enExample) |
| LT (1) | LT3029144T (enExample) |
| PL (2) | PL2403951T3 (enExample) |
| PT (2) | PT2403951E (enExample) |
| SI (2) | SI3029144T1 (enExample) |
| SM (2) | SMT201900565T1 (enExample) |
| WO (1) | WO2010101921A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2403951T3 (en) | 2009-03-02 | 2016-01-11 | Univ California | Tumor-selective E1a and E1b adenoviral mutants |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| EP3022320B2 (en) | 2013-07-19 | 2024-09-25 | Ludwig Institute for Cancer Research Ltd | Whole-genome and targeted haplotype reconstruction |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| US10906957B2 (en) | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| CN110741081B (zh) * | 2017-01-30 | 2024-07-23 | 埃皮辛特瑞柯斯公司 | 肿瘤选择性tata盒和caat盒突变体 |
| CA3052090A1 (en) * | 2017-01-30 | 2018-08-02 | Epicentrx, Inc. | Multiple transgene recombinant adenovirus |
| AU2018253088B2 (en) * | 2017-04-10 | 2024-09-19 | Epicentrx, Inc. | Method for producing recombinant virus |
| EA201990822A1 (ru) * | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| MX2019014059A (es) * | 2017-05-24 | 2020-07-28 | Epicentrx Inc | Adenovirus antiangiogenico. |
| KR102702230B1 (ko) | 2017-05-26 | 2024-09-03 | 에피센트알엑스, 인코포레이티드 | 트랜스진을 보유하는 재조합 아데노바이러스 |
| KR102757384B1 (ko) | 2017-09-27 | 2025-01-20 | 에피센트알엑스, 인코포레이티드 | 면역조절 융합 단백질 |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| CA3094329A1 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3844286A1 (en) * | 2018-08-31 | 2021-07-07 | Orca Therapeutics B.V. | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells |
| US12680122B2 (en) | 2019-10-08 | 2026-07-14 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
| CN114262691A (zh) * | 2020-09-16 | 2022-04-01 | 杭州康万达医药科技有限公司 | 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
| CN118931897B (zh) * | 2024-06-27 | 2026-01-16 | 中山大学 | 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643567A (en) | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5352775A (en) | 1991-01-16 | 1994-10-04 | The Johns Hopkins Univ. | APC gene and nucleic acid probes derived therefrom |
| CA2113990A1 (en) | 1991-07-26 | 1993-02-18 | Frederick L. Moolten | Cancer therapy utilizing malignant cells |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| WO1995007994A2 (en) * | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| US5902925A (en) | 1996-07-01 | 1999-05-11 | Integrated Sensor Solutions | System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
| PT1135514E (pt) * | 1999-01-28 | 2009-07-20 | Onyx Pharma Inc | Vectores de vaivém adenovirais com deleção em e1b |
| US6764674B1 (en) * | 1999-01-28 | 2004-07-20 | Onyx Pharmaceuticals Inc. | Adenovirus E1B shuttle vectors |
| AU2001257611A1 (en) * | 2000-04-28 | 2001-11-12 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| US6884613B2 (en) * | 2000-08-25 | 2005-04-26 | The General Hospital Corporation | Selective precipitation of viruses |
| CN1183250C (zh) | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| GB0117198D0 (en) * | 2001-07-13 | 2001-09-05 | Btg Int Ltd | Anti-neoplastic viral agents |
| US20040219516A1 (en) * | 2002-07-18 | 2004-11-04 | Invitrogen Corporation | Viral vectors containing recombination sites |
| US20040106184A1 (en) * | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| WO2005052143A2 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| JP5484897B2 (ja) * | 2007-04-20 | 2014-05-07 | タカラバイオ株式会社 | 遺伝子治療のためのベクター |
| DK2403951T3 (en) | 2009-03-02 | 2016-01-11 | Univ California | Tumor-selective E1a and E1b adenoviral mutants |
-
2010
- 2010-03-02 DK DK10749205.0T patent/DK2403951T3/en active
- 2010-03-02 ES ES15182086T patent/ES2750305T3/es active Active
- 2010-03-02 EP EP22178897.9A patent/EP4123030A1/en active Pending
- 2010-03-02 US US13/254,825 patent/US9073980B2/en active Active
- 2010-03-02 KR KR1020187012031A patent/KR102020018B1/ko active Active
- 2010-03-02 WO PCT/US2010/025926 patent/WO2010101921A2/en not_active Ceased
- 2010-03-02 PL PL10749205T patent/PL2403951T3/pl unknown
- 2010-03-02 EP EP15182086.7A patent/EP3029144B1/en active Active
- 2010-03-02 PL PL15182086T patent/PL3029144T3/pl unknown
- 2010-03-02 KR KR1020117022884A patent/KR101752910B1/ko active Active
- 2010-03-02 LT LT15182086T patent/LT3029144T/lt unknown
- 2010-03-02 SI SI201031944T patent/SI3029144T1/sl unknown
- 2010-03-02 PT PT107492050T patent/PT2403951E/pt unknown
- 2010-03-02 HR HRP20151396T patent/HRP20151396T1/hr unknown
- 2010-03-02 KR KR1020197025813A patent/KR102150027B1/ko active Active
- 2010-03-02 EP EP19171420.3A patent/EP3591059B1/en active Active
- 2010-03-02 HU HUE10749205A patent/HUE026386T2/en unknown
- 2010-03-02 SI SI201031077T patent/SI2403951T1/sl unknown
- 2010-03-02 EP EP10749205.0A patent/EP2403951B1/en active Active
- 2010-03-02 SM SM20190565T patent/SMT201900565T1/it unknown
- 2010-03-02 JP JP2011553041A patent/JP6072414B2/ja active Active
- 2010-03-02 HU HUE15182086A patent/HUE046565T2/hu unknown
- 2010-03-02 PT PT151820867T patent/PT3029144T/pt unknown
- 2010-03-02 DK DK15182086.7T patent/DK3029144T3/da active
- 2010-03-02 ES ES10749205.0T patent/ES2557812T3/es active Active
- 2010-03-02 KR KR1020177017391A patent/KR101922539B1/ko active Active
-
2015
- 2015-05-26 US US14/722,021 patent/US20160017294A1/en not_active Abandoned
- 2015-08-12 JP JP2015159434A patent/JP6375273B2/ja active Active
- 2015-12-31 SM SM201500329T patent/SMT201500329B/it unknown
-
2018
- 2018-02-28 JP JP2018035231A patent/JP6817979B2/ja active Active
- 2018-08-08 US US16/058,886 patent/US10876097B2/en active Active
-
2019
- 2019-10-03 HR HRP20191808TT patent/HRP20191808T1/hr unknown
- 2019-10-10 CY CY20191101067T patent/CY1122385T1/el unknown
-
2020
- 2020-02-07 JP JP2020019294A patent/JP2020078326A/ja active Pending
- 2020-11-20 US US17/100,671 patent/US11618888B2/en active Active
-
2021
- 2021-09-29 JP JP2021158698A patent/JP7326396B2/ja active Active
-
2022
- 2022-11-23 US US17/993,182 patent/US12195766B2/en active Active
-
2024
- 2024-12-05 US US18/969,407 patent/US20250327037A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malogolovkin et al. | Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes | |
| Wong et al. | Oncolytic viruses for cancer therapy: overcoming the obstacles | |
| Cheng et al. | Oncolytic replication of E1b-deleted adenoviruses | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| EP4043021A3 (en) | Oncolytic tumor viruses and methods of use | |
| ES2557812T3 (es) | Mutantes de E1a y E1b de adenovirus selectivos de tumor | |
| Ko et al. | Development of transcriptionally regulated oncolytic adenoviruses | |
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| Kim et al. | Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy | |
| JP2019523008A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| JP2016527920A5 (enExample) | ||
| JP2019528793A5 (enExample) | ||
| Javid et al. | The role of viruses in cancer development versus cancer therapy: An oncological perspective | |
| Niedźwiedzka-Rystwej et al. | The double-edged sword role of viruses in gastric cancer | |
| JP2018518986A5 (enExample) | ||
| Yokoda et al. | Oncolytic virotherapy in upper gastrointestinal tract cancers | |
| Xu et al. | HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy | |
| JP2016530890A5 (enExample) | ||
| Chia et al. | A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy | |
| JP4361954B2 (ja) | アデノウィルス核酸を含有する医薬用組成物 | |
| Gao et al. | A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs | |
| Thomas et al. | Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors | |
| Hoffmann et al. | Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli | |
| Wei et al. | Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells |